secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001558370-24-014663
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance
--------------------------------------------------------------------------------

- Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.
- Adjusted EBITDA $30.7M, +64% YoY; adjusted diluted EPS $0.35 vs $0.14 prior year.
- Updated FY2025 guidance: net sales $1.05B-$1.10B; Adjusted EBITDA $124M-$132M (15% growth).
- Discontinued atopic dermatitis project; expects ~$200M sales from Zoetis MFA portfolio in FY2025.
- Gross margin improved 280 bps to 32.1%; interest expense up $3.1M due to refinancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/0001558370-24-014663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024014663/pahc-20241105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer